IMPORTANT

If you are in any doubt about any of the contents of this document, you should seek independent professional advice.

Suzhou Genhouse Bio Co., Ltd.
勤浩醫藥（蘇州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

[REDACTED]

Number of [REDACTED] under the [REDACTED]	**:**	**[REDACTED] H Shares (subject to the [REDACTED])**
Number of [REDACTED]	**:**	**[REDACTED] H Shares (subject to adjustment)**
Number of [REDACTED]	**:**	**[REDACTED] H Shares (subject to adjustment and the [REDACTED])**
[REDACTED]	**:**	**HK$[REDACTED] per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)**
Nominal Value	**:**	**RMB[REDACTED] per H Share**
[REDACTED]	**:**	**[•]**

Sole Sponsor, **[REDACTED]**

华泰国际
HUATAI INTERNATIONAL

[REDACTED]

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

A copy of this document, having attached thereto the documents specified in "Documents Delivered to the **[REDACTED]** of Companies and Available for Display" in Appendix V to this document, has been registered by the **[REDACTED]** of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission and the **[REDACTED]** of Companies in Hong Kong take no responsibility for the contents of this document or any other document referred to above.

The **[REDACTED]** is expected to be determined by agreement between the **[REDACTED]** (for itself and on behalf of the **[REDACTED]**) and us on the **[REDACTED]**. The **[REDACTED]** is expected to be on or around **[REDACTED]** and, in any event, not later than 12:00 noon on **[REDACTED]**. The **[REDACTED]** will not be more than HK$**[REDACTED]** and is currently expected to be not less than HK$**[REDACTED]**. Investors applying for the **[REDACTED]** may be required to pay, on application (subject to application channels), the **[REDACTED]** of HK$**[REDACTED]** for each Share together with a brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%, subject to refund if the **[REDACTED]** is less than HK$**[REDACTED]** per **[REDACTED]**.

The **[REDACTED]** (for itself and on behalf of the **[REDACTED]**) with the consent of our Company, may reduce the number of **[REDACTED]** and/or the indicative **[REDACTED]** below that stated in this document (which is HK$**[REDACTED]** to HK$**[REDACTED]** per **[REDACTED]**) at any time prior to the morning of the last day for lodging applications under the **[REDACTED]**. In such a case, notices of the reduction in the number of **[REDACTED]** and/or the indicative **[REDACTED]** will be published on our website at **https://www.genhousebio.com** not later than the morning of the last day for lodging applications under the **[REDACTED]**. Such notice will also be available at the website of the **[REDACTED]** at **www.hkex.com.hk**. Further details are set out in "**[REDACTED]**" and "How to Apply for **[REDACTED]**". If, for any reason, the **[REDACTED]** (for itself and on behalf of the **[REDACTED]**) and we are unable to reach an agreement on the **[REDACTED]** by 12:00 noon on **[REDACTED]**, the **[REDACTED]** will not become unconditional and will lapse immediately.

Prior to making an investment decision, prospective investors should consider carefully all of the information set out in this document, including the risk factors set out in "Risk Factors". The obligations of the [REDACTED] under the [REDACTED] to subscribe for, and to procure [REDACTED] for, the [REDACTED], are subject to termination by the [REDACTED] (for itself and on behalf of the [REDACTED]) if certain events shall occur prior to 8:00 a.m. on the day that trading in the Shares commence on the [REDACTED]. Such grounds are set out in "[REDACTED]". It is important that you refer to that section for further details.

The **[REDACTED]** have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be **[REDACTED]**, sold, pledged or transferred, except pursuant to an exemption from, or in a transaction subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. The **[REDACTED]** are being **[REDACTED]** and sold (i) in the United States solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to Rule 144A or another available exemption from registration requirements under the U.S. Securities Act and (ii) only outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. No **[REDACTED]** of the **[REDACTED]** will be made in the United States.

[REDACTED]

IMPORTANT

[REDACTED]

IMPORTANT

[REDACTED]